<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834184</url>
  </required_header>
  <id_info>
    <org_study_id>VFCE-2008-002</org_study_id>
    <nct_id>NCT00834184</nct_id>
  </id_info>
  <brief_title>Safety and PK of Nikkomycin Z in Healthy Subjects</brief_title>
  <official_title>Phase I, Randomized, Double-blind, Placebo Controlled, Multiple-dose Evaluation of the Safety Tolerance and Pharmacokinetics of Nikkomycin Z in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if nikkomycin Z is safe when administered at&#xD;
      different dose levels for 14 days. The study will also determine blood levels and urinary&#xD;
      excretion of nikkomycin Z in relation to dose administered. Healthy patients will be eligible&#xD;
      to participate and will be allocated to receive nikkomycin Z (various doses) or a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will serve as a Phase I, randomized, double-blind, placebo controlled,&#xD;
      multiple-dose study to evaluate the safety, tolerance and pharmacokinetics of nikkomycin Z.&#xD;
      Nikkomycin Z has previously been studied in a single dose protocol in healthy male subjects.&#xD;
      This study is designed to run in parallel to protocol VFCE-2007-001 to provide additional&#xD;
      data on safety and pharmacokinetics. The study will involve a total of 32 subjects (6&#xD;
      active/2 placebo per group) with a multiple, rising dose strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine safety and tolerance of nikkomycin Z in healthy subjects following administration of multiple doses.</measure>
    <time_frame>four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the multiple dose pharmacokinetics of nikkomycin Z in healthy subjects</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nikkomycin Z 250 mg BID versus placebo BID x 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nikkomycin Z 500 mg BID versus placebo BID x 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nikkomycin Z 750 mg BID versus placebo BID x 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nikkomycin Z 750 mg TID versus placebo TID x 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nikkomycin Z</intervention_name>
    <description>Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.&#xD;
250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years and &lt;= 40 years&#xD;
&#xD;
          -  Male or Female (if female, must have a negative pregnancy test and agrees to use an&#xD;
             acceptable contraception method)&#xD;
&#xD;
          -  Able to understand study and give written informed consent&#xD;
&#xD;
          -  Be determined healthy based on a medical and laboratory evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18 years or over 40 years&#xD;
&#xD;
          -  Inability to comprehend study and provide written informed consent&#xD;
&#xD;
          -  Inability to comply with the study requirements&#xD;
&#xD;
          -  History of or current evidence of major organ disease including:&#xD;
&#xD;
          -  Renal disease - serum creatinine &gt; 1.5 mg/dL, significant hematuria or proteinuria,&#xD;
             known structural abnormality or chronic kidney disease&#xD;
&#xD;
          -  Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C,&#xD;
             bilirubin &gt; 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver&#xD;
             disease, other chronic liver disease&#xD;
&#xD;
          -  CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections,&#xD;
             stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental&#xD;
             status changes&#xD;
&#xD;
          -  Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major&#xD;
             lung disease&#xD;
&#xD;
          -  Cardiac disease - history or current evidence of ischemic coronary artery disease,&#xD;
             myocardial infarction, heart failure, significant arrhythmia&#xD;
&#xD;
          -  Gastrointestinal disease - presence of inflammatory bowel disease, difficulty&#xD;
             swallowing, or any gastrointestinal problem that would limit taking oral medications&#xD;
             or that may compromise absorption of oral medications&#xD;
&#xD;
          -  Cancer - History of hematologic malignancy or solid tumor excluding basal cell&#xD;
             carcinoma limited to the skin within the past 5 years&#xD;
&#xD;
          -  History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus&#xD;
&#xD;
          -  Any other history or evidence of disease that in the opinion of the physician would&#xD;
             increase the risk for the subject for clinical trial participation&#xD;
&#xD;
          -  Immunocompromised state - solid organ transplant, cancer chemotherapy, BMT with graft&#xD;
             versus host disease, immunosuppressive therapy, or HIV infection&#xD;
&#xD;
          -  Recent weight loss of greater than 10%&#xD;
&#xD;
          -  Regular use of prescription medications, over-the-counter medications, or&#xD;
             dietary/herbal supplements within 14 days of day 1. Occasional use of acetaminophen or&#xD;
             over-the-counter NSAID within the 14 day window may be allowed at the P.I.'s&#xD;
             discretion&#xD;
&#xD;
          -  Subjects who received another investigational drug within 30 days of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Nix, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical &amp; Translational Research Center - University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nikkomycin Z</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nikkomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

